Eloxx Pharmaceuticals, Inc. (ELOX) Key Metrics
ELOX valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $52.6M
- Enterprise value
- $53.7M
- P/E (TTM)
- 3.7
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 1.2
- EV / EBITDA
- 0.1
- Dividend yield
- —
- Beta
- −171,332.88
ELOX key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsELOX returns How much profit the business earns on the capital it uses.
ELOX financial health Debt, liquidity and how easily interest is covered.
ELOX returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
ELOX debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
ELOX key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Per share | ||||||||||
| Revenue per share | $0.00 | — | — | — | — | — | — | — | — | — |
| Earnings per share | −$5.34 | — | — | — | — | — | — | — | — | — |
| Operating cash flow per share | −$5.64 | — | — | — | — | — | — | — | — | — |
| Free cash flow per share | −$5.64 | — | — | — | — | — | — | — | — | — |
| Cash per share | $4.27 | — | — | — | — | — | — | — | — | — |
| Book value per share | −$10.61 | — | — | — | — | — | — | — | — | — |
| Tangible book value per share | −$10.61 | — | — | — | — | — | — | — | — | — |
| Capex per share | $5.64 | — | — | — | — | — | — | — | — | — |
| Debt per share | $0.89 | — | — | — | — | — | — | — | — | — |
| Shares outstanding | 1.1M | — | — | — | — | — | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | — | — | — | — | −409.2% | −148.9% | −128.6% | −146.8% | −163.7% | −98.5% |
| Return on invested capital (ROIC) | — | — | — | — | — | — | — | — | — | −46.4% |
| Return on assets (ROA) | −145.4% | −134.1% | −149.4% | −108.9% | −186.3% | −81.0% | −92.8% | −125.0% | −124.8% | −57.5% |
| Return on tangible assets | −113.8% | −105.6% | −996.1% | −170.7% | −147.8% | −130.6% | −86.3% | −93.0% | −85.6% | −734.3% |
| Free cash flow margin | — | −74.1% | — | — | — | — | — | — | — | — |
| Financial health | ||||||||||
| Total debt | $1.0M | $6.5M | $4.0M | $13.4M | $13.5M | $12.0M | $15.8M | — | — | — |
| Cash & short-term investments | $4.8M | $111,000 | $1.1M | $19.5M | $42.6M | $24.7M | $56.3M | $48.7M | $24.2M | $810,808 |
| Net debt | −$3.8M | $6.4M | $2.8M | −$6.1M | −$29.1M | −$12.7M | −$40.6M | −$48.7M | −$24.2M | −$810,808 |
| Debt / equity | — | — | — | — | 0.60 | 1.18 | 0.44 | — | — | — |
| Debt / assets | 0.19 | 2.19 | 2.32 | 0.63 | 0.30 | 0.45 | 0.27 | — | — | — |
| Current ratio | 0.31 | 0.11 | 0.07 | 0.87 | 4.37 | 2.63 | 4.89 | 6.45 | 7.16 | 2.66 |
| Quick ratio | 0.31 | 0.11 | 0.07 | 0.87 | 4.37 | 2.63 | 4.89 | 6.45 | 7.16 | 2.66 |
| Interest coverage | -6.1 | -2.2 | -15.0 | -17.7 | -33.6 | -20.9 | -31.3 | — | -30.5 | — |
| Working capital | −$11.9M | −$24.3M | −$21.1M | −$3.0M | $33.5M | $16.1M | $45.9M | $42.5M | $21.1M | $613,637 |
| Invested capital | −$15.7M | −$17.9M | −$19.8M | −$16.7M | −$6.7M | −$2.5M | −$4.3M | −$5.7M | −$2.8M | $3.7M |
| Tangible asset value | −$11.9M | −$24.3M | −$22.6M | −$10.7M | $22.4M | $10.2M | $36.2M | $42.9M | $21.4M | −$3.5M |
| Net current asset value | −$11.9M | −$24.3M | −$22.8M | −$11.7M | $20.7M | $9.6M | $35.0M | $42.5M | $21.1M | −$3.7M |
| Graham net-net per share | −$11.03 | — | — | — | — | — | — | — | — | — |
| Capital allocation | ||||||||||
| Capex / revenue | — | 0.0% | — | — | — | — | — | — | — | 0.0% |
| Capex / depreciation | — | 0.00 | 0.00 | 0.09 | 0.09 | 0.00 | 0.07 | 1.09 | 6.08 | 0.00 |
| Stock-based compensation / revenue | — | 8.5% | — | — | — | — | — | — | — | — |
| R&D / revenue | — | 56.3% | — | — | — | — | — | — | — | 2,786.1% |
| SG&A / revenue | — | 82.6% | — | — | — | — | — | — | — | — |
| Efficiency | ||||||||||
| Days sales outstanding | — | 78.0 | — | — | — | — | — | — | — | — |
| Days payables outstanding | — | — | — | 1,155.1 | 353.6 | 751.7 | 854.7 | 1,923.9 | 14,319.2 | — |
| Receivables turnover | 0.00 | 4.68 | — | — | — | — | 0.00 | — | — | — |
| Payables turnover | — | 0.00 | — | 0.32 | 1.03 | 0.49 | 0.43 | 0.19 | 0.03 | — |
| Asset turnover | 0.00 | 2.71 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Average receivables | $1.4M | $1.4M | $0 | — | — | — | $26,000 | — | — | — |
| Average payables | $4.0M | $5.5M | $4.4M | $2.2M | $930,000 | $1.2M | $1.3M | $1.1M | $1.5M | — |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 87.8% |
Computed from ELOX's annual financial statements (latest annual report filed March 17, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
ELOX valuation and financial ratios
Based on the latest twelve months, the trailing P/E is 3.7. It ended the year with $1.0 million of debt and $4.8 million in cash and short-term investments, a net cash position of $3.8 million.
See the ELOX income statement, the ELOX chart for price history, or the ELOX stock overview for the latest quote and news.
ELOX key metrics FAQ
What is Eloxx Pharmaceuticals's P/E ratio?
Eloxx Pharmaceuticals's trailing P/E ratio is 3.7 based on the last twelve months of earnings (as of October 17, 2026). At the end of fiscal 2025 it was —.
How much debt does Eloxx Pharmaceuticals have?
Eloxx Pharmaceuticals had total debt of $1.0 million at the end of fiscal 2025 and more cash than debt.
What is Eloxx Pharmaceuticals's current ratio?
Eloxx Pharmaceuticals's current ratio was 0.31 at the end of fiscal 2025: current assets were 0.31 times current liabilities.